Skip to main content
Annals of Clinical and Translational Neurology logoLink to Annals of Clinical and Translational Neurology
. 2021 Mar 30;8(4):1005. doi: 10.1002/acn3.51341

Corrigendum 2 for acn3.753

PMCID: PMC8045902  PMID: 33852200

In Jun et al. (2019), an error was introduced during the proofreading process. At the end of the first paragraph of the Discussion section, a P value was written as “p ‐> P value” instead of “P value”. The corrected paragraph is below:

To our knowledge, this is the first randomized controlled study to investigate the effect of PRM in patients with iRBD. The results found that neither low‐dose nor higher‐dose PRM improved the frequency or severity of RBD symptoms over the 4‐week trial period, and there were no significant differences from the placebo in the primary or secondary outcomes. Although the difference in the RBDQ‐KR Factor 2 score decreased from 36.4 to 31.8 at 4 weeks after treatment with PRM 6 mg/day, the standard deviation was relatively high and its P value did not show a trend toward statistical significance (P = 0.477).

We apologize for this error.


Articles from Annals of Clinical and Translational Neurology are provided here courtesy of Wiley

RESOURCES